PhRMA Awards Celebrate Breakthroughs – And Get Warning On Prices
Executive Summary
Merck's Keytruda highlights promise of FDA designation, but Tom Brokaw notes perils of industry's pricing strategy.
You may also be interested in...
Breakthrough's Achilles Heel: Alexion’s Newly Acquired Kanuma Delayed By Manufacturing
FDA extends the PDUFA date for enzyme replacement therapy by three months so agency can review chemistry, manufacturing and controls information; another drug, Strensiq, is also pending at FDA without any action.
FDA Soft Sells GMP Quality Overhaul For Generics; Don’t Be ‘Anxious,’ Woodcock Says
‘In some ways our practices have played into the problems we’ve been having,’ CDER director tells GPhA annual meeting as she outlines her plan to ‘radically change’ manufacturing oversight.
Pink Sheet Podcast: Medicare Inflation Rebates And Negotiation, Leqembi Reimbursement, US FDA Gene Therapy Chief
Pink Sheet reporter and editors discuss the first round of mandated Medicare inflation rebates and new guidance on price negotiations, consider the VA’s decision to cover the Alzheimer’s drug Leqembi, and the US FDA continuing to search for a cell and gene therapy office leader.